NEW YORK (GenomeWeb News) — Molecular Detection and Launch Diagnostics today announced an exclusive distribution agreement for MDI's real-time PCR-based diagnostic for methicillin-resistant Staphylococcus aureus.
The agreement covers the UK, France, and Republic of Ireland. Other terms of the agreement were not disclosed.
The two firms also announced that the test, called Detect-Ready MRSA, has been launched in the UK and the Republic of Ireland.
Detect-Ready MRSA is a qualitative RT-PCR in vitro diagnostic test for detecting MRSA nasal colonization and is used to help prevent bacterial infection in hospitals and other healthcare settings.
Based in Wayne, Pa., MDI develops molecular diagnostic tests. Launch Diagnostics, headquartered in Longfield, UK, is a distributor of reagents, instruments, and related consumables.